FUS/TLS as a Co-Activator of Androgen Receptor in Prostate Cancer Cells
Author Information
Author(s): Haile Simon, Lal Aaron, Myung Jae-Kyung, Sadar Marianne D., Kyprianou Natasha
Primary Institution: Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada
Hypothesis
FUS/TLS interacts with the androgen receptor and enhances its transcriptional activity in prostate cancer cells.
Conclusion
FUS is a novel co-activator of the androgen receptor that enhances its transcriptional activity and promotes the proliferation of prostate cancer cells.
Supporting Evidence
- FUS was identified as an AR-interacting protein through co-immunoprecipitation.
- Depletion of FUS reduced androgen-dependent proliferation of LNCaP cells.
- FUS was recruited to the enhancer region of the PSA gene in response to androgens.
- Overexpression of FUS increased AR transcriptional activity in a dose-dependent manner.
- FUS expression was modulated by androgen treatment in vitro and in vivo.
Takeaway
FUS helps the androgen receptor work better in prostate cancer cells, which helps the cancer grow.
Methodology
The study used co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation, and luciferase reporter assays to analyze the interaction between FUS and the androgen receptor.
Limitations
The study primarily focused on in vitro experiments, which may not fully replicate in vivo conditions.
Participant Demographics
The study used LNCaP human prostate cancer cells and PC3 prostate cancer cells.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website